Navigation Links
LA BioMed investigator Dr. Christina Wang spearheads study on new male contraceptive gel
Date:6/28/2012

Christina Wang, M.D., lead investigator at Los Angeles Biomedical Research Institute (LA BioMed) one of the leading biomedical research institutes in the country recently completed a study utilizing a new contraceptive gel that has the potential to be developed as a user controlled chemical birth control agent for males. The gel, which contains testosterone and a synthetic progestin called Nestorone, sharply lowers sperm counts in men with few side effects. The study conducted at LA BioMed and the University of Washington is funded by the National Institutes of Child Health and Human Development (NICHD).

Dr. Wang and her team, along with the team at the University of Washington, enrolled 99 men in a preliminary study of the drug combination. One third of them received a gel containing testosterone and a placebo, which was applied for six months. The remaining two thirds received a gel containing testosterone and one of the two concentrations of Nestorone. Fifty-six men completed at least 20 weeks of the study and adhered to the protocol.

The results of the study were reported at the recent Endocrine Society Meeting & Expo in Houston. Of the men receiving the drug combination, 88 to 89 percent achieved a sperm concentration of less than 1 million sperm per milliliter, while those receiving testosterone and the placebo achieved the same low sperm concentration in 23 percent of men. Depending on the dosage, there was a complete absence of sperm in 78 and 69 percent of the men receiving the drug combination, and in 23 percent of the men receiving testosterone and the placebo.

"Up until now, the responsibility for contraception has traditionally always been with the female," said Dr. Wang. "With these new contraceptive methods for males, the responsibility will be shared. While this gel has great potential and minimal side effects, it does warrant further study as a male contraceptive."

Dr. Wang is a renowned andrologist/endocrinologist and a world leader in efforts to develop a safe, effective and reversible hormonal male contraceptive. In addition to this study, she is also working on a Phase I single dose and multiple dose study that tests the safety and tolerability of a new androgen dimethandrolone undecanoate that is being developed as a potential male contraceptive agent by the National Institute of Child Health and Human Development.


'/>"/>

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. LA BioMed investigators, Drs. Kevin Bruhn and Noah Craft, develop novel treatment for melanoma
2. UMMS researcher Victor Ambros, Ph.D., named co-recipient of 2012 Janssen Award for Biomedical Research
3. UCSC physicist Alexander Sher named Pew Scholar in the Biomedical Sciences
4. Applied nanobiomedicine: Exploiting nanoparticles to hunt for hidden cancer cells
5. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
6. LA BioMed receives Grand Challenges Explorations grant
7. Biomedical researchers receive Hartwell Foundation awards
8. LA BioMeds Dr. John Tsuang examines effects of Ibudilast and metamphetamines
9. Leading health care quality expert is 2012 AcademyHealth Distinguished Investigator
10. Damon Runyon Cancer Research Foundation awards $3.3 million to 8 top young clinical investigators
11. Pediatric kidney expert receives Young Investigator Award from American Transplant Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... Facing medical needs with a newborn boy ... advantage of a new benefit for employees that is uncommon in American business: 12 ... company supports me and other employees as new parents. It keeps our family life ...
(Date:7/25/2017)... ... ... SignatureCare Emergency Center – South Austin is treating both adult and pediatric patients ... The Emergency Room opened early March, making it the first SignatureCare Emergency ... are running smoothly,” said Aaron Braun, SignatureCare Emergency Center’s Chief Medical Officer. “We’re glad ...
(Date:7/24/2017)... ... July 24, 2017 , ... Contact: ... Robins & Morton, Perkins Will, Newcomb & Boyd, Walter P Moore and ... new Destination Medical Building located at Mayo Clinic in Jacksonville, Florida. , ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... SignatureCare ... scholarship will be awarded for the fall semester to a deserving student. Get ... Centers Spring 2017 scholarship was awarded to Mariana Castillo who is a nursing student ...
(Date:7/24/2017)... ... July 24, 2017 , ... BayMark Health Services has been ... Administration’s (SAMHSA) State Targeted Response to the Opioid Crisis program. The funding, ... the development of a hub and spoke model for opioid treatment in California. ...
Breaking Medicine News(10 mins):
(Date:7/17/2017)... , July 17, 2017  MedX Holdings, Inc., the ... testing, strengthening and rehabilitation equipment, today announced the national ... MedX is considered the gold standard for the treatment ... specialized medical strengthening equipment. ... with the physician or practice who prescribe the MedX ...
(Date:7/13/2017)... 13, 2017 RK Logistics Group, Inc. was awarded ... for its Fremont, CA headquarters facility ... Tri-Valley and San Jose for hi-tech, ... Fremont , with its Fremont Innovation District, is excited ... a powerful resource to the hundreds of biotech, pharma and ...
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
Breaking Medicine Technology: